SG Americas Securities LLC Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE)

SG Americas Securities LLC lessened its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 82.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,732 shares of the medical instruments supplier's stock after selling 8,100 shares during the quarter. SG Americas Securities LLC's holdings in Haemonetics were worth $135,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Nordea Investment Management AB raised its position in Haemonetics by 5.5% in the 4th quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock worth $8,152,000 after purchasing an additional 5,385 shares during the period. Geode Capital Management LLC grew its holdings in Haemonetics by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock worth $95,986,000 after acquiring an additional 21,547 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Haemonetics in the 3rd quarter worth $382,000. XTX Topco Ltd grew its holdings in Haemonetics by 84.9% in the 3rd quarter. XTX Topco Ltd now owns 8,450 shares of the medical instruments supplier's stock worth $679,000 after acquiring an additional 3,880 shares during the last quarter. Finally, Zacks Investment Management grew its holdings in Haemonetics by 11.5% in the 3rd quarter. Zacks Investment Management now owns 16,921 shares of the medical instruments supplier's stock worth $1,360,000 after acquiring an additional 1,740 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Up 0.3 %

NYSE HAE traded up $0.18 during trading hours on Friday, reaching $62.47. 1,333,274 shares of the company's stock traded hands, compared to its average volume of 1,042,682. Haemonetics Co. has a 52-week low of $58.80 and a 52-week high of $97.97. The firm has a market cap of $3.14 billion, a PE ratio of 24.59, a PEG ratio of 0.98 and a beta of 0.39. The firm has a 50-day simple moving average of $74.55 and a 200 day simple moving average of $77.58. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HAE. Needham & Company LLC cut their price target on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a report on Friday, February 7th. StockNews.com raised shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $95.00 to $68.00 in a report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price target on the stock. Finally, JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.